Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intersect ENT Inc    XENT

INTERSECT ENT INC

(XENT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intersect ENT, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2019 | 01:47pm EDT

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intersect ENT, Inc. (“Intersect” or “the Company”) (NASDAQ: XENT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's shares between August 1, 2018 and May 6, 2019, inclusive (the “Class Period”), are encouraged to contact the firm before July 15, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall, or Sherin Mahdavian, of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Intersect failed to maintain the necessary force of reimbursement representatives to ensure physicians’ access to SINUVA, its sinus implant. This caused the Company’s sales force to concentrate on helping with reimbursement as opposed to driving sales growth. Physicians became less likely to adopt the Company’s products due to transaction costs and delays in reimbursement. Intersect eventually hired staff to address these issues. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Intersect, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on INTERSECT ENT INC
08/05INTERSECT ENT : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
08/01INTERSECT ENT : 2Q Earnings Snapshot
AQ
08/01INTERSECT ENT, INC. : Results of Operations and Financial Condition, Financial S..
AQ
08/01INTERSECT ENT : Reports Second Quarter 2019 Results
BU
07/25INTERSECT ENT, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/25INTERSECT ENT : Announces FDA Approval of New PROPEL Mini Straight Delivery Syst..
BU
07/15INTERSECT ENT : to Report Second Quarter 2019 Financial Results
BU
06/27INTERSECT ENT, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
06/27INTERSECT ENT : Announces Appointment of Thomas A. West as CEO
BU
06/27UPCOMING DEADLINE ALERT : The Schall Law Firm Announces it is Investigating Clai..
BU
More news
Financials (USD)
Sales 2019 108 M
EBIT 2019 -46,9 M
Net income 2019 -44,8 M
Finance 2019 30,5 M
Yield 2019 -
P/E ratio 2019 -11,1x
P/E ratio 2020 -12,1x
EV / Sales2019 4,33x
EV / Sales2020 3,86x
Capitalization 500 M
Chart INTERSECT ENT INC
Duration : Period :
Intersect ENT Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTERSECT ENT INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 25,14  $
Last Close Price 15,90  $
Spread / Highest target 145%
Spread / Average Target 58,1%
Spread / Lowest Target 6,92%
EPS Revisions
Managers
NameTitle
Lisa D. Earnhardt President, Chief Executive Officer & Director
Christine R. Kowalski Chief Operating Officer
Jeryl L. Hilleman Chief Financial Officer
Dana George Mead Independent Director
Frederic H. Moll Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INTERSECT ENT INC-42.58%509
MEDTRONIC PLC17.54%139 719
BAXTER INTERNATIONAL INC.32.13%44 863
HOYA CORPORATION32.41%30 013
ZIMMER BIOMET HOLDINGS33.59%28 448
TERUMO CORP-46.08%22 806